

	1-(3-Fluoro-5-methylsulfonyl-pyridin-2-yl)-7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-1H,2H,3H-imidazo[4,5-c]quinolin-2-one
	8-[1-(Azetidin-3-yl)-3-methyl-1H-pyrazol-4-yl]-1-(3-fluoro-5-methoxypyridin-4-yl)-7-methoxy-3-methyl-1H,2H,3H-imidazo[4,5-c]quinolin-2-one

and/or pharmaceutically usable derivative, salt, solvate, tautomer, stereoisomer thereof, including mixtures thereof in all ratios

19. Compound according to one of Claims 1 to 18 and/or pharmaceutically usable derivative, salt, solvate, tautomer, or stereoisomer thereof, for use as medicament.

20. Use of a compound according to one of Claims 1 to 18 and/or pharmaceutically usable derivative, salt, solvate, tautomer, or stereoisomer thereof, in the manufacture of a medicament for the treatment of diseases in which the inhibition/regulation and/or modulation of ATM kinase signal transduction plays a role or for use in the treatment of diseases which are influenced by inhibition of ATM kinase.

21. Use of a compound according to one of Claims 1 to 18 and/or pharmaceutically usable derivative, salt, solvate, tautomer, or stereoisomer thereof, in the manufacture of a medicament for the treatment of cancer, tumours and/or metastases.

22. The use of a compound or pharmaceutically usable derivative salt, solvate, tautomer, stereoisomer thereof according to Claim 20 or 21, wherein when the treatment is for cancer, tumours and/or metastases, the medicament is to be used in combination with radiotherapy.

23. The use of a compound or pharmaceutically usable derivative salt, solvate, tautomer, stereoisomer thereof according to Claim 20 or 21, wherein when the treatment is for cancer, tumours and/or metastases, the medicament is to be used in combination with at least one anticancer agent.

24. Use of a compound according to one of Claims 1 to 18 and/or pharmaceutically usable derivative, salt, solvate, tautomer, or stereoisomer thereof, in the manufacture of a medicament for the sensitisation of cancer cells to an anticancer agent and/or ionising radiation.

25. The use of a compound or pharmaceutically usable derivative salt, solvate, tautomer, stereoisomer thereof according to one of Claims 20 - 23, where the tumour is selected from the group of diseases of squamous epithelium, bladder, stomach, kidneys, head, neck, oesophagus, cervix, thyroid, intestine, bone, liver, brain, prostate, urogenital tract, lymphatic system, larynx, lung, skin, blood and immune system, and/or the cancer is selected from the group of monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma, intestinal carcinoma, breast carcinoma, acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia, chronic lymphatic leukaemia, Hodgkin's lymphoma and non-Hodgkin's lymphoma.

26. Pharmaceutical composition comprising an effective amount of at least one compound according to one of Claims 1 to 18 and/or a pharmaceutically usable derivative, salt, solvate, tautomer, or stereoisomer thereof, optionally together with at least one pharmaceutically tolerated excipient.

27. Pharmaceutical composition according to Claim 26, furthermore comprising at least one further medicament active compound, preferably at least one anticancer agent.

28. The use of a kit consisting of separate packs of
(a) an effective amount of a compound according to one of Claims 1 to 18 and/or pharmaceutically usable derivative, salt, solvate, tautomer, or stereoisomer thereof, and
(b) an effective amount of a further medicament active compound, preferably an anticancer agent in the manufacture of a medicament for the treatment of cancer, tumours and/or metastases.

29. Use of a compound according to one of Claims 1 to 18 and/or pharmaceutically usable derivative, salt, solvate, tautomer or stereoisomer thereof, in the manufacture of a medicament for the inhibition of a protein kinase.

30. Use of a compound according to one of Claims 1 to 18 and/or pharmaceutically usable derivative, salt, solvate, tautomer or stereoisomer thereof, for the inhibition of ATM kinase *in vitro*.

31. Process for the preparation of a medicament comprising:

- i. determination that a concentration at which a compound according to one of Claims 1 to 18 and/or pharmaceutically usable derivative, salt, solvate, tautomer, or stereoisomer thereof, achieves 50% inhibition of the activity of ATM kinase is 500 nM or less, and
- ii. preparation of a pharmaceutical composition which comprises the compound.

32. The process according to claim 31, wherein 50% inhibition of the activity of ATM kinase is 100nM or less.

33. The use of a compound according to one of Claims 1 to 18 and/or pharmaceutically usable derivative, salt, solvate, tautomer, or stereoisomer thereof, in the manufacture of a medicament for the treatment of cancer and/or tumors wherein during the process of manufacture of the medicament, determination that a concentration at which the compound according to one of Claims 1 to 18 and/or pharmaceutically usable derivative, salt, solvate, tautomer, or stereoisomer thereof, achieves 50% inhibition of the activity of ATM kinase is 500 nM or less is first performed followed by the preparation of the medicament in the form of a pharmaceutical composition comprising the compound.

34. The use according to claim 33, wherein 50% inhibition of the activity of ATM kinase is 100nM or less.

35. ATM Inhibitor, selected from a compound according to one of Claims 1 to 18, and/or pharmaceutically usable derivative, salt, solvate, tautomer, or stereoisomer thereof.